Consistent with results from USP14 overexpression and loss-of-function analyses, treatment with USP14 inhibitors promotes the degradation of a variety of proteotoxic proteins within cells, including those highly implicated in neurodegenerative diseases—such as tau, TDP-43, ATXN3, and PrPSC [8,34,67,68]. The gene discussed is USP14; the disease is neurodegenerative disease.